Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo

Figures & data

Table 1. Characterization of various kinds of LPNs.

LPNs	Mean diameter (nm)	PDI	Zeta potential (mV)	DTX EE (%)	CUR EE (%)	DTX DL (%)	CUR DL (%)
DTX-CUR-LPNs	169.6 ± 4.6	0.16 ± 0.06	−35.7 ± 1.9	89.8 ± 3.1	81.9 ± 5.6	5.5 ± 0.8	5.8 ± 0.6
DTX-CUR-NPs	116.4 ± 2.2	0.08 ± 0.02	−31.1 ± 2.9	80.2 ± 4.3	72.5 ± 3.6	8.3 ± 1.2	9.6 ± 1.7
DTX-LPNs	167.2 ± 3.9	0.13 ± 0.04	−26.4 ± 2.7	88.3 ± 2.9	NA	9.1 ± 1.4	NA
CUR-LPNs	168.1 ± 4.2	0.14 ± 0.05	−23.2 ± 2.3	NA	82.6 ± 3.9	NA	10.4 ± 1.9
LPNs	163.3 ± 3.8	0.11 ± 0.03	−18.5 ± 1.6	NA	NA	NA	NA

Figure 1. In vitro release of DTX from different LPNs systems.

Figure 2. In vitro release of CUR from different LPNs systems.

Figure 3. In vitro cytotoxicity assays of LPNs, NPs, and free drugs.

Table 2. IC₅₀ values of different formulations.

Formulations	DTX-CUR-LPNs	DTX-CUR-NPs	DTX-LPNs	CUR-LPNs	Free DTX	Free CUR
IC50 DTX (μM)	0.42 ± 0.07	1.81 ± 0.21	0.94 ± 0.16	NA	8.91 ± 0.67	NA
IC50 CUR (μM)	0.84 ± 0.12	3.62 ± 0.65	NA	3.62 ± 0.34	NA	16.62 ± 1.13

Table 3. Optimization of DTX to CUR ratios in DTX-CUR-LPNs.

DTX to CUR ratios (w/w)	5:1	2:1	1:1	1:2	1:5
IC50 DTX (μM)	1.24 ± 0.36	0.92 ± 0.16	0.89 ± 0.13	0.43 ± 0.08	0.96 ± 0.19
Praticle size (nm)	175.1 ± 5.2	166.5 ± 4.4	168.3 ± 4.2	171.6 ± 3.9	172.4 ± 3.8

Figure 4. In vivo antitumor efficacy of LPNs, NPs, and free drugs.